IntroductionBone marrow and organ transplantation are curative for an increasing number of diseases. The major barriers are graft-versushost disease (GVHD) and rejection, which currently are inhibited by toxic nonspecific immunosuppression. Induction of donorspecific tolerance without the requirement for immunosuppressive drugs would be highly desirable. Adoptive therapy with ex vivo-induced antigen (Ag)-specific T regulatory cells (Tregs) has considerable potential.CD4 ϩ CD25 high Foxp3 ϩ T cells are potent regulators of transplantation rejection 1-5 and GVHD. [6][7][8] Natural Tregs are produced as a separate lineage in the thymus that constitute 2% to 10% of peripheral CD4 ϩ T cells, 9 inhibit in a non-Ag-specific manner, and protect normal tissue from immune injury. 2,10 The CD4 ϩ CD25 ϩ T cells that mediate transplantation tolerance are Ag-specific, 1-4 but how they develop and differ to natural non-Ag-specific CD4 ϩ CD25 ϩ Tregs is poorly understood. 9 In fully allogeneic models, naive CD4 ϩ CD25 high T cells, if given at a ratio of 1:1 with naive CD4 ϩ T cells, can totally prevent rejection 5 and GVHD 7 but only partially block GVHD at a ratio of 1:2. 8 At a ratio of 1:10, naive CD4 ϩ CD25 high T cells do not block rejection 5 or GVHD. 7 Given the very low number of CD4 ϩ CD25 ϩ T cells in the T-cell population, it is impractical to prepare enough cells for therapeutic usage at a ratio of 1:1. Ex vivo polyclonal activation of CD4 ϩ CD25 ϩ T cells with interleukin-2 (IL-2) and anti-CD3 monoclonal antibody (mAb) 6 or IL-2, anti-CD3 and anti-CD28 11 results in 200-to 250-fold cell number expansion but no enhanced Ag-specific regulatory capacity. 12 Culture of CD4 ϩ CD25 ϩ Tregs with allo-Ag and IL-2 for a week or more also increases cell numbers but does not induce high potency Agspecific CD4 ϩ CD25 ϩ Tregs, in that a ratio of 2:1 13 or 5:1 14 with naive T cells is required to suppress skin graft rejection. Similarly, in GVHD, a 7:10 ratio of IL-2-and allo-Ag-cultured Tregs to naive cells is less effective than fresh naive CD4 ϩ CD25 ϩ T cells, in that they delay but do not fully prevent GVHD. 8 In contrast, CD4 ϩ CD25 ϩ T cells within CD4 ϩ T cells from hosts with allo-Ag-specific tolerance to a graft can transfer allo-Ag-specific tolerance at an effective ratio of less than 1:20. 2,3 These tolerant CD4 ϩ T cells, when cultured in vitro, lose the capacity to transfer tolerance unless stimulated by specific donor Ag in media supplemented with T-cell cytokines. 2,15,16 Which cytokines are most effective at maintaining specific Tregs is unknown, but IL-2 alone is insufficient. 16 This suggests that Ag-specific CD4 ϩ CD25 ϩ T cells may become dependent on cytokines other than IL-2. We have identified that interferon-␥ (IFN-␥) and IL-5, but not other T-helper 1 (Th1) and Th2 cytokines, promoted proliferation and survival of Agspecific tolerance mediating Tregs from rats tolerant to an allograft (B.M.H., M.N., K.M.P., N.D.V., G.T.T., S.J.H., unpublished data). 20 we examined whether Th1 and Th2 cytokines promote...

Immune responses to foreign and selfAgs can be controlled by regulatory T cells (Tregs) expressing CD4 and IL-2R␣ chain (CD25). Defects in Tregs lead IntroductionBoth Ag-specific 1 and naive regulatory T cells (Tregs) 2-4 that control immune responses are mainly CD4 ϩ CD25 ϩ T cells 5 expressing transcription factor FOXP3. 6 Autoimmunity occurs with the breakdown in immune tolerance to self-Ag and can be because of a failure of natural Tregs (nTregs) produced by the thymus which prevent spontaneous autoimmune activation of CD4 ϩ CD25 Ϫ T effector cells by inhibiting APCs. 5 nTregs maintain immune homeostasis and are polyclonally expanded by IL-2. nTregs can suppress all immune responses, because they are not Ag specific. To fully suppress high ratios to effector lineage, CD4 ϩ CD25 Ϫ T cells are required, usually Ͼ 1:1; whereas the natural ratio of these cells in peripheral lymphoid tissues is tightly regulated to Ͻ 1:10. 7,8 There is ample evidence for Ag-specific Treg induction in vivo, including T-cell transfer of tolerance to specific autoantigen induced by immunization with autoantigen without complete Freund adjuvant (CFA), 9 the parabiosis of tolerance to autoimmunity from normal hosts, 10 and the epitope specificity of tolerance induction with an autoantigen. 11 Ag-specific CD4 ϩ CD25 ϩ Tregs have phenotypic and functional differences from the nTreg, recently reviewed by Hall et al. 12 Activated Tregs do not migrate from blood to lymph but express chemokine receptors and other ligands that promote their migration to sites of inflammation, where they control local inflammation. 12 Further, their action is not to inhibit APCs via CTLA4, but to inhibit or eliminate activated effector T cells and macrophages, by a variety of mechanisms. 12 To date, most studies focused on nTregs that suppress in a non-Ag-specific manner and must be present at high ratios with effector T cells to fully suppress an immune response. In autoimmune disease it would be desirable to induce Ag-specific Tregs that can suppress only the specific immune response at low ratios (Ͻ 1:10) to effector cells. 13 Specific immune tolerance, as occurs in adult rodents that accept an allograft long term, is mediated by Ag-specific CD4 ϩ CD25 ϩ Tregs that suppress at ratios Ͻ 1:10. 1,14,15 These alloantigen-specific Tregs are difficult to identify, because their survival depends on stimulation by both Ag 1,16 and T cell-derived cytokines. 17 IL-2 17 or IL-4 do not fully maintain activated Agspecific Tregs, but other cytokines such as IL-5 can. 3 In our studies, the initial activation of nTregs to alloantigenspecific Tregs occurred when they were cultured with specific alloantigens and either the T helper type 1 (Th1) cytokine IL-2 or the Th2 cytokine IL-4, but not other Th1 or Th2 cytokines. 3 Alloactivation of nTregs with IL-2 induces the receptor for the late Th1 cytokine IFN-␥ (Ifn␥r) but not the receptor for the Th2 cytokine ␤, Ifn␥r. 3 The selective induction of Il-5r␣ on Ag-activated Tregs that have been stimulated by IL-4, not IL-2, ra...

Synthetic cannabinoid receptor agonists (SCRAs) are a dynamic class of new psychoactive substances (NPS), with novel chemotypes emerging each year. Following the putative detection of 5F-CUMYL-P7AICA in Australia in 2016, the scaffold-hopping SCRAs 5F-CUMYL-PICA, 5F-CUMYL-PINACA, and 5F-CUMYL-P7AICA were synthesized and characterized by nuclear magnetic resonance (NMR) spectroscopy, gas chromatography-mass spectrometry (GC-MS), and liquid chromatography-quadrupole time-of-flight-MS (LC-QTOF-MS). Since little is known of the pharmacology of 7-azaindole SCRAs like 5F-CUMYL-P7AICA, the binding affinities and functional activities of all compounds at cannabinoid type 1 and type 2 receptors (CB and CB , respectively) were assessed using tritiated radioligand competition experiments and fluorescence-based plate reader membrane potential assays. Despite CB binding affinities differing by over two orders of magnitude (K = 2.95-174 nM), all compounds were potent and efficacious CB agonists (EC = 0.43-4.7 nM), with consistent rank order for binding and functional activity (5F-CUMYL-PINACA >5F-CUMYL-PICA >5F-CUMYL-P7AICA). Additionally, 5F-CUMYL-P7AICA was found to exert potent cannabimimetic effects in mice, inducing hypothermia (6°C, 3 mg/kg) through a CB -dependent mechanism.

Synthetic cannabinoids (SC) are the largest class of new psychoactive substances (NPS), and are increasingly associated with serious adverse effects. The majority of SC NPS are 1,3-disubstituted indoles and indazoles featuring a diversity of subunits at the 1- and 3-positions. Most recently, cumyl-derived indole- and indazole-3-carboxamides have been detected by law enforcement agencies and by emergency departments. Herein we describe the synthesis, characterization, and pharmacology of SCs CUMYL-BICA, CUMYL-PICA, CUMYL-5F-PICA, CUMYL-PINACA, CUMYL-5F-PINACA, and related analogues. All cumyl-derived SCs were potent, efficacious agonists at CB (EC = 0.43-12.3 nM) and CB (EC = 11.3-122 nM) receptors in a fluorometric assay of membrane potential, with selectivity for CB activation (3.1-53 times over CB). CUMYL-PICA and CUMYL-5F-PICA were evaluated in rats using biotelemetry, and induced hypothermia and bradycardia at doses of 1 mg/kg. Hypothermia was reversed by pretreatment with a CB, but not CB, antagonist, confirming that cumyl-derived SCs are cannabimimetic in vivo.